CGTX Quote, Financials, Valuation and Earnings

Merck & has a net margin of -- compared to Cognition Therapeutics's net margin of 18.95%. Cognition Therapeutics's return on equity of -- beat Merck &'s return on equity of 29.26%.

Cognition Therapeutics has a consensus price target of $6.20, signalling upside risk potential of 798.91%. On the other hand Merck & has an analysts' consensus of $130.34 which suggests that it could grow by 29.8%. Given that Cognition Therapeutics has higher upside potential than Merck &, analysts believe Cognition Therapeutics is more attractive than Merck &.

Cognition Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck & has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.989%.

Cognition Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.15% to investors and pays a quarterly dividend of $0.81 per share. Cognition Therapeutics pays -- of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend.

Cognition Therapeutics quarterly revenues are --, which are smaller than Merck & quarterly revenues of $16.7B. Cognition Therapeutics's net income of -$9.9M is lower than Merck &'s net income of $3.2B. Notably, Cognition Therapeutics's price-to-earnings ratio is -- while Merck &'s PE ratio is 20.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cognition Therapeutics is -- versus 3.99x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

MetaVia has a net margin of -- compared to Cognition Therapeutics's net margin of --. Cognition Therapeutics's return on equity of -- beat MetaVia's return on equity of --.

Cognition Therapeutics has a consensus price target of $6.20, signalling upside risk potential of 798.91%. On the other hand MetaVia has an analysts' consensus of $16.00 which suggests that it could grow by 658.29%. Given that Cognition Therapeutics has higher upside potential than MetaVia, analysts believe Cognition Therapeutics is more attractive than MetaVia.

Cognition Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MetaVia has a beta of -0.223, suggesting its less volatile than the S&P 500 by 122.274%.

Cognition Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MetaVia offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cognition Therapeutics pays -- of its earnings as a dividend. MetaVia pays out -- of its earnings as a dividend.

Cognition Therapeutics quarterly revenues are --, which are smaller than MetaVia quarterly revenues of --. Cognition Therapeutics's net income of -$9.9M is lower than MetaVia's net income of -$5.7M. Notably, Cognition Therapeutics's price-to-earnings ratio is -- while MetaVia's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cognition Therapeutics is -- versus -- for MetaVia. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Cognition Therapeutics's net margin of -49.65%. Cognition Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Cognition Therapeutics has a consensus price target of $6.20, signalling upside risk potential of 798.91%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 496%. Given that Cognition Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Cognition Therapeutics is more attractive than NovaBay Pharmaceuticals.

Cognition Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Cognition Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cognition Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Cognition Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Cognition Therapeutics's net income of -$9.9M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Cognition Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cognition Therapeutics is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

ZyVersa Therapeutics has a net margin of -- compared to Cognition Therapeutics's net margin of --. Cognition Therapeutics's return on equity of -- beat ZyVersa Therapeutics's return on equity of --.

Cognition Therapeutics has a consensus price target of $6.20, signalling upside risk potential of 798.91%. On the other hand ZyVersa Therapeutics has an analysts' consensus of $70.00 which suggests that it could grow by 1734.86%. Given that ZyVersa Therapeutics has higher upside potential than Cognition Therapeutics, analysts believe ZyVersa Therapeutics is more attractive than Cognition Therapeutics.

Cognition Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ZyVersa Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Cognition Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ZyVersa Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cognition Therapeutics pays -- of its earnings as a dividend. ZyVersa Therapeutics pays out -- of its earnings as a dividend.

Cognition Therapeutics quarterly revenues are --, which are smaller than ZyVersa Therapeutics quarterly revenues of --. Cognition Therapeutics's net income of -$9.9M is lower than ZyVersa Therapeutics's net income of -$2.4M. Notably, Cognition Therapeutics's price-to-earnings ratio is -- while ZyVersa Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cognition Therapeutics is -- versus -- for ZyVersa Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.